Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3638 - Holistic therapeutic strategy of TNBC necessitates in depth molecular classification: a prospective study


11 Sep 2017


Poster display session


Breast Cancer


Rittwika Bhattacharyya


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


R. Bhattacharyya1, K. Banerjee2, M. Sen1, A. Mukhopadhyay1

Author affiliations

  • 1 Molecular Biology, Netaji Subhas Chandra Bose Cancer Research Institute, 700016 - Kolkata/IN
  • 2 Molecular Biology, Saroj Gupta Cancer Centre and Research Institute, 700063 - Kolkata/IN


Abstract 3638


Triple negative breast cancer (TNBC), the most heterogeneous and aggressive breast cancer has always remained a global burden. To understand the molecular pathogenesis, we stratified the seven subgroups of TNBC propounded by Lehmann et al (2011) as: [1] TNBC with alterations of the DNA damage repair and cell cycle checkpoint pathways (Basal Like 1 & 2 (BL1, BL2)), [2] with upregulation of cell signalling and cell motility pathways (mesenchymal (M), mesemchymal stem like (MSL)), [3] with upregulated cell survival pathways (BL2, M, MSL) [4] With upregulated angiogenesis pathways (BL2, MSL), [5] With upregulation of pathways associated with T cell signalling, [6] With upregulated Androgen receptor signalling pathways. Our objective was to prioritize the basic molecular heterogeneity of TNBC in redefining our choice of drugs.


Lehmann’s TNBC subgroups showed deregulation of diverse molecular pathways necessitating targeted therapeutics. We conducted a Meta-Analysis on12 randomized reported trial cases (n = 1170), solely under the following classes of drug regimens: [1] DNA destabilizers, [2] PARP inhibitors, [3] Microtubule stabilizers, [4] Angiogenesis inhibitors, [5] Antimetabolite, [6] T cell targeted therapy; as single or combinational therapies. Radiotherapy recipients were excluded.


Best therapeutic efficacies of DNA destabilizers with angiogenesis inhibitors in combination than monotherapy with either (OR: 5.011-7.286; p value< 0.001) indicated a significant prevalence of basal like TNBCs in populations. Statistical significance with antimetabolites as combination therapy (OR: 2.343; p value: 0.018) and not with microtubule stabilizer (OR: 0.377) were remarkable, indicating probability of less predominance of M or MSL type TNBC in a population. PARP inhibitors or T cell targeted therapies were also found promising (OR: 1.120, 1.040 respectively), warranting their targeted usage for BRCA1 deficient and IM type TNBCs respectively.


For TNBC treatment, personalized medicine and not a generalized treatment strategy should be considered.

Clinical trial identification


Legal entity responsible for the study

Netaji Subhas Chandra Bose Cancer Research Institute




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.